Payer Perspectives in Major Depressive Disorder (MDD)

Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP, open a discussion surrounding payer considerations relating to the treatment of major depressive disorder (MDD).

Expert panelists discuss the lack of diversity among available treatment options for MDD.

Consequences attributed to poorly controlled and recurrent MDD are evaluated by Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP.

Major depressive disorder treatment failure can lead to subsequent costs and poor outcomes, affecting payer considerations in the treatment landscape.

Key opinion leaders discuss the importance of early effective treatment for patients with MDD.

Panelists provide their key considerations when determining appropriate treatment options for patients with major depressive disorder.

Drs Cannon and Rothrock provide insights into their process for defining value among newly launched MDD treatments.

Managed care experts discuss health disparities among various patient populations affected by MDD.

Expert panelists explore prevalence and disparities of MDD across patient populations.

Key social determinants affecting MDD are evaluated by Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP.

Jay Weaver, PharmD, MPH, and Mona Chitre, PharmD, CGP, discuss the increased demand for mental health services since the COVID-19 pandemic.

Payers provide insights to health care disparities currently impacting patients with major depressive disorder (MDD).

Drs Chitre and Weaver explore social and health care disparities more prominently affecting various MDD patient populations.

Key social determinants of health impacting MDD are discussed by expert payer panelists.

Drs Weaver and Chitre illustrate a population health approach strategy for MDD.

Expert panelists consider factors affecting treatment adherence for patients with MDD.

Drs Weaver and Chitre share strategies to support MDD treatment adherence across their patient populations.

Drs Weaver and Chitre discuss aligning key considerations for payers and goals of therapy for patients in the treatment of MDD.

Early effective treatment strategies can have a significant impact on long-term effects for patients with MDD.

Drs Chitre and Weaver share their finals thoughts, highlighting key contributors to long-term outcomes for patients with major depressive disorder.